This is a working overview of Fifteen residues, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-29 and is reviewed periodically as new material appears.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Tulips are mainly distributed along a band corresponding to latitude 40° north, from southeast of Europe (Greece, Albania, North Macedonia, Kosovo, Southern Serbia, Bulgaria, most part of Romania, Ukraine, Russia) and Turkey in the west, through the Levant (Syria, Israel, Palestinian Territories, Lebanon and Jordan) and the Sinai Peninsula. From there it extends eastwards through Jerevan (Armenia), and Baku (Azerbaijan) and on the eastern shore of the Caspian Sea through Turkmenistan, Bukhara, Samarkand and Tashkent (Uzbekistan), to the eastern end of the range in the Pamir-Alai and Tien-Shan mountains in Central Asia, which form the centre of diversity. Further to the east, Tulipa is found in the western Himalayas, southern Siberia, Inner Mongolia, and as far as the northwest of China. While authorities have stated that no tulips west of the Balkans are native, subsequent identification of Tulipa sylvestris subsp. australis as a native of the Iberian Peninsula and adjacent North Africa shows that this may be a simplification. In addition to these regions in the west tulips have been identified in Greece, Cyprus and the Balkans. In the south, Iran marks its furthest extent, while the northern limit is Ukraine. Although tulips are also found throughout most of the Mediterranean and Europe, these regions do not form part of the natural distribution. Tulips were brought to Europe by travellers and merchants from Anatolia and Central Asia for cultivation, from where they escaped and naturalised (see map).
A representative of the Swedish Olympic Committee said, "I see it as ill-conceived, short-sighted and foolhardy and something other than sport." The UK Anti-Doping organisation said in a statement that "UKAD's mission is to protect sport from doping cheats. There is no place in sport for performance enhancing drugs, nor the Enhanced Games." Travis Tygart, CEO of the United States Anti-Doping Agency (USADA), said: "farcical … likely illegal in many [US] states" and "a dangerous clown show, not real sport." Rahul Gupta, director of the Office of National Drug Control Policy, stated that the Biden administration had deep concerns regarding TEG. The China Anti-Doping Agency (CHINADA) stated that it is in "firm opposition to any attempt to portray doping as so-called scientific advancements, and calls on the global sports community to stand united in rejecting the Enhanced Games." TEG filed a lawsuit in the United States District Court for the Southern District of New York in Manhattan against several sporting bodies in August 2025, including World Aquatics and WADA. The allegation is that these organizations are violating anti-trust laws by preventing athletes from competing in TEG. United States District Judge Jesse Furman dismissed the lawsuit in a 33-page order in November 2025. The organization chose not to refile the lawsuit within the 30-day deadline, and the court closed the case.
== Characterization == Solution precipitation as a core synthesis technique produces homogenous-sized nanoparticles, which can be advantageous in controlling specific physical properties such as surface tension and packing density of the atoms in a crystalline lattice structure. The most common methods of characterizing nanoparticle size distribution and morphology of the core in aquasomes include scanning electron microscopy (SEM) and transmission electron microscopy (TEM). In a study by Kommimeni et al. in 2012, researchers employed TEM to verify that the ceramic particles were spherical and also in the acceptable nano-range for aquasomes. The carbohydrate coating size can also be characterized using SEM and TEM, but Fourier-transform infrared spectroscopy (FTIR) is commonly utilized to check for the presence of the coat. In a study by Kommimeni et al. in 2020, FTIR was used to confirm the presence of the coating by analyzing the IR spectra bands that correspond to the functional groups of either the core or the sugar coat. The bioactive drug loaded onto the aquasome can be characterized in a variety of ways depending on the molecular classification of the drug. In Kossovsky et al. in 1996, which studied the effect of insulin as the bioactive drug of interest, immunogold labeling was employed. Through this technique, the different binding efficiencies of carbohydrate coatings for insulin were able to be observed.
Sources: en.wikipedia.org
=== West === In the West, one of the first known mentions of freeze-dried tofu was by Paillieux in 1880, "Sometimes during the winter tofu is frozen, then dried to give it a sponge-like texture. In this state, it lasts a long time and can be cooked in various ways." Trimble mentioned the koya-dofu in the United States in 1896. It was mentioned as kori-tofu in 1899. In 1904, a mention appeared in the article "The Use of Frost in Making Japanese Foods," by Loew. In 1906, Senft, a member of the German Military Food Administration, mentioned koya-dofu as a preserved food used by the Japanese military during the Russo-Japanese War.
The disparity in the countries' economic conditions means that many Yemenis head to Saudi Arabia to find work. Saudi Arabia does not have a barrier with its other neighbours in the Gulf Cooperation Council, whose economies are more similar to its own. In 2006 Saudi Arabia proposed constructing a security fence along the entire length of its 900 kilometre long desert border with Iraq. As of July 2009 it was reported that Saudis will pay $3.5 billion for a security fence. The combined wall and ditch will be 965 kilometres (600 miles) long and include five layers of fencing, watch towers, night-vision cameras, and radar cameras and manned by 30,000 troops. Elsewhere in Europe, the Republic of Macedonia began erecting a fence on its border with Greece in November 2015. In 2003, Botswana began building a 480 kilometres (300 miles) long electric fence along its border with Zimbabwe. The official reason for the fence is to stop the spread of foot-and-mouth disease among livestock. Zimbabweans argue that the fence's height is clearly intended to keep people out. Botswana has responded that the fence is designed to keep out cattle and to ensure that entrants have their shoes disinfected at legal border crossings. Botswana also argued that the government continues to encourage legal movement into the country. Zimbabwe was unconvinced, and the barrier remains a source of tension.
paracellular transport The transfer of substances across an epithelium by passing through the extracellular space between cells, in contrast to transcellular transport, where substances travel through cells by crossing the intracellular cytoplasm.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.